Skip Navigation
Skip to contents

ICDM 2018

Research group and committee session

Diabetes together with NAFLD :
Translational understanding for NAFLD in T2D
16:00~17:30 / Thursday 11 October
Convention Hall B 4F
Chairman: TBD
Overview

Organizer: KDA research group on fatty liver disease

This session entitled with 'diabetes together with NAFLD' is translational session and designed to provide a place for clinicians and basic researchers to understand the novel pathophysiologies and potential therapeutic areas for NAFLD in patient with diabetes. In this session, a variety of therapeutic targets based on the novel NAFLD pathophysiologies especially in T2D patients, including autophagy, inflammasone, FXR/PPARa, organokines and important immunologic regulators, will be presented and discussed. This session will be the first step toward better understanding the importance of NAFLD in T2D.
Hyon-Seung Yi
Chungnam National University, Korea
Hyon-Seung Yi
RG1-1 Growth differentiation factor 15: an important immunometabolic regulator in hepatic inflammation and insulin resistance
Yong Ho Lee
Yonsei University, Korea
Yong Ho Lee
RG1-2 New therapeutic approaches for non-alcoholic steatohepatitis: autophagy and inflammasome
David Moore
Baylor University, USA
David Moore
RG1-3 Nutrient sensing nuclear receptors control liver energy balance
Kyung Mook Choi
Korea University, Korea
Kyung Mook Choi
RG1-4 Organokines and non-alcoholic fatty liver disease (NAFLD)
Clinical trials in Korea:
Noteworthy clinical trials in Korean type 2 diabetes
09:00~10:40 / Friday 12 October
Flamingo
Chairman: TBD
Overview

Organizer: Committee of Clinical Practice Guideline

This session entitled with 'clinical trials in Korea' is clinical session and designed to provide a place for clinicians to understand the noteworthy clinical trials in Korean patients with type 2 diabetes. In this session, results of clinical trials of Korean patients with type 2 diabetes, including degludec, liraglutide, dapagliflozin, evogliptin, and teneligliptin, will be presented and discussed. By understanding the results of clinical studies conducted in Koreans, we will help to understand the characteristics and treatment directions of diabetes in Koreans.
Nan Hee Kim
Korea University, Korea
Sin Gon Kim
RG2-1 Efficacy and safety of lixisenatide in Korean type 2 diabetic patients with basal insulin failure
Min Kyong Moon
Seoul National University, Korea
Min Kyong Moon
RG2-2 Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Korean
Sang Youl Rhee
Kyung Hee University, Korea
Sang Youl Rhee
RG2-3 Liraglutide provides similar glycemic control as glimepiride
Kyu Yeon Hur
Sungkyunkwan University, Korea
RG2-4
RG2-4 Effect of dapagliflozin in Korean patients with type 2 diabetes who have inadequate glycemic control with glimepiride
Eun Seok Kang
Yonsei University, Korea
Eun Seok Kang
RG2-5 Teneligliptin vs. sitagliptin in Korean
Jung Hyun Noh
Inje University, Korea
Jung Hyun Noh
RG2-6 Efficacy and safety of evogliptin in Korean patients with type 2 diabetes
Seung-Hyun Ko
The Catholic University of Korea, Korea
Seung-Hyun Ko
RG2-7 Conclusion
Diabetes in Asia :
Sharing real experience of diabetes epidemiologic research
16:20~18:00 / Friday 12 October
Convention hall C
Chairman: TBD
Overview

Organizer: Committee of International Liaison

This session entitled with 'Diabetes in Asia' is a clinical session and designed to make an international occasion for gathering of Asian experts (clinicians and epidemiologic researchers) in diabetes care. The representatives participating speakers and panels from more than 10 countries from all over the Asia will present and discuss their experience in diabetes prevention, perspectives and their healthcare system. The ultimate goal of this session resides in continuous collaboration and friendship among the Asian countries and diabetes societies in the prevention and management of diabetes in Asia in the future.
Takashi Kadowaki
University of Tokyo, Japan
Takashi Kadowaki
RG3-1 Diabetes prevention study in Japan
Ronald C.W. Ma
Chinese University of Hong Kong, Hong Kong
Ronald C.W. Ma
RG3-2 Developmental origins of T2D: a perspective from China
Dae Jung Kim
Ajou University, Korea
Dae Jung Kim
RG3-3 Diabetes epidemic and diabetes care system in Korea
Panel Discussion
Touch Khun (Preah Kossamak Hospital, Cambodia)
Altaisaikhan Khasag (Mongolian National University, Mongolia)
Ikram Shah Ismail (University of Malaya, Malaysia)
Wannee Nitiyanant (Mahidol University, Thailand)
Diabetes guideline :
Diabetes guidelines in perspectives of Asian diabetes phenotype
09:00~11:00 / Saturday 13 October
Emerald Hall B
Chairman: TBD
Overview

Organizer: Committee of Clinical Practice Guideline

This session entitled with 'diabetes guidelines' is clinical session and designed to provide a place for clinicians to understand the cardiovascular risk factor targets in Asian patient with diabetes. In this session, optimal blood pressure goals, LDL cholesterol management (moderate vs. high intensity statin) and glycemic control goals (HbA1c <6.5% vs. <7%) in Asian diabetes will be presented and discussed. This session will provide updated cardiovascular risk factor targets in diabetes.
Mee Kyoung Kim
The Catholic University of Korea, Korea
RG4-1
RG4-1 Optimal blood pressure control target in Asian diabetes; the lower, the better?
Hiroshi Itoh
Keio University, Japan
TBD
RG4-2 LDL-C management in Asian diabetes; moderate vs. high intensity statin - a lesson from EMPATHY study
Dae Jung Kim
Ajou University, Korea
TBD
RG4-3 Glycemic control target in Asian diabetes: HbA1c < 6.5% vs. < 7%?
Panel Discussion
Sang Yong Kim(Chosun University, Korea)
Jung Hyun Noh(Inje University, Korea)
Eun Jung Rhee(Sungkyunkwan University, Korea)
Diabetes drug, approval, insurance :
Solutions to differences in diabetes drug aproval and insurance standards
09:00~11:00 /
Saturday 13 October Flamingo
Chairman: TBD
Overview
TBD
TBD
RG5-1 Principles of setting up drug insurance standards, focusing on diabetes drugs
TBD
TBD
RG5-2 Proposal for the principle of diabetes drug insurance application
TBD
TBD
RG5-3 TBD
TBD
TBD
RG5-4 TBD
Panel Discussion
KFDA (Ministry of Food and Drug satety)
HIRA (Health insurance review & assessment service)